TherapeuticsMD, Inc. (TXMD) Stock Price & Analysis
TherapeuticsMD, Inc. (TXMD) — MoonshotScore 34/100 (Weak band), calculated Nov 18, 2026. Price $1.81 (-5.24%), as of the Nov 18, 2026 trading session; market cap $21.0M.
Educational signal · not a buy or sell recommendation · How to read this
TherapeuticsMD, Inc. · TXMD · NASDAQ
TherapeuticsMD, Inc. is a U.S.-based women's healthcare company focused on developing and commercializing prescription products for conditions like dyspareunia and vasomotor symptoms, alongside a contraceptive system and prenatal vitamins. The company maintains an active preclinical pipeline and distributes its products through wholesale and retail pharmacy channels.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · TherapeuticsMD (TXMD)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strained balance sheet; the market is already moving on it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Average; Financial Safety: Strained; Valuation: Fair; Growth Durability: Flat; Momentum: Rising.
- quarterly revenue $784,000 (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 1 of the last 4 reports
- Altman Z -33.89 · Piotroski F 6
Holding back: balance-sheet strain
Helping: an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 25 | Weak | |
| 25 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.81 | |
| Change on the day | -5.24% | |
| 52-week range | $1.43 – $2.95 | |
| Market capitalisation | $21.0M | — |
| Price / earnings (trailing) | 181.90 | |
| Shares traded on the day | 21.9K |
Price & events
Other perspectives
Council score for TherapeuticsMD (TXMD): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Four of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens, Klarman-style lens and Moon AI lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is TherapeuticsMD (TXMD), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. TherapeuticsMD, Inc. (TXMD) is listed on NASDAQ. It employs 1 people and is led by Marlan D. Walker. In Q3 FY2025 it reported revenue of $784,000 and net income of $152,000. The market values it at $21.0M.
What do the latest results show for TherapeuticsMD (TXMD)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $784,000. Against analyst estimates the company has EPS beat 1 of the last 4 reports.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $784,000 | $152,000 | $0.01 (diluted) |
| Q4 FY2025 | $893,000 | -$619,000 | — |
What are the financial strengths and risks for TherapeuticsMD (TXMD)?
Short answer
The MoonshotScore pillars rate an attractive price, positive momentum as strengths. What is holding it back is balance-sheet strain. The distress and quality screens read Altman Z -33.89 · Piotroski F 6. Trailing ratios: ROE 0.6% · ROA -2.3% · current ratio 3.32.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -33.89 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 4 reported quarters.
What should you watch next at TherapeuticsMD (TXMD)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $9.30M · EPS 0.17 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q3 FY2025) was filed Nov 12, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does TherapeuticsMD compare with its peers?
Short answer
TherapeuticsMD's score ranks 3rd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1.75 Nov 18, 2026 | $22.0M | 48 5-pillar Nov 18, 2026 | |
| $0.68 Nov 18, 2026 | $95.5M | 35 5-pillar Nov 18, 2026 | |
| TherapeuticsMD (TXMD) — this page | $1.81 | $21.0M | 34 |
| $3.82 Nov 18, 2026 | $18.2M | 32 5-pillar Nov 18, 2026 | |
| $1.50 Nov 18, 2026 | $71.1M | 32 5-pillar Nov 18, 2026 | |
| $0.80 Nov 18, 2026 | $41.6M | 31 5-pillar Nov 18, 2026 | |
| $1.52 Nov 18, 2026 | $9.77M | 30 5-pillar Nov 18, 2026 | |
| $3.49 Nov 18, 2026 | $45.3M | 30 5-pillar Nov 18, 2026 | |
| $6.10 Nov 18, 2026 | $24.2M | 25 5-pillar Nov 18, 2026 | |
| $2.66 Nov 18, 2026 | $28.9M | 25 5-pillar Nov 18, 2026 | |
| $0.60 Nov 18, 2026 | $10.8M | 25 5-pillar Nov 18, 2026 | |
| $0.51 Nov 18, 2026 | $22.0M | 23 5-pillar Nov 18, 2026 | |
| $2.82 Nov 18, 2026 | $28.1M | 23 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $9.30M
- EPS estimate
- $0.17
Measured against a quoted price of $1.81 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 4
- Purchases
- 5
- Sales
- 0
- Other transactions
- 7
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held TXMD in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported TXMD in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about TherapeuticsMD (TXMD)?
TherapeuticsMD Stock: Key Questions Answered
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for TXMD?
TXMD carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is TXMD a good stock to buy?
Stock Expert AI does not rate TXMD buy, sell or hold. TherapeuticsMD, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the TXMD stock price today?
The last price recorded for TherapeuticsMD, Inc. (TXMD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for TXMD?
TherapeuticsMD, Inc. (TXMD) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. Specialized Women's Healthcare Focus: The company exclusively targets the women's health market with products for dyspareunia, vasomotor symptoms, contraception, and prenatal nutrition. Not financial advice.
How frequently does TXMD data refresh on this page?
TXMD's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven TXMD's recent stock price performance?
TherapeuticsMD, Inc. (TXMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on women's healthcare, addressing specific and prevalent conditions with targeted products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TXMD overvalued or undervalued right now?
The trailing P/E of TherapeuticsMD, Inc. (TXMD) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of TXMD?
Fractional-share availability for TherapeuticsMD, Inc. (TXMD) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
How can I track TXMD's earnings and financial reports?
TherapeuticsMD, Inc. (TXMD) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for TXMD earnings announcements.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 10 from Financial Modeling Prep (FMP), 9 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com